Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

RJ. Motzer, A. Bex, P. Russo, Y. Tomita, HJ. Cutuli, C. Rojas, M. Gross-Goupil, G. Schinzari, B. Melichar, P. Barthélémy, A. Ruiz Garcia, J. Sosman, MO. Grimm, JC. Goh, C. Suarez, CK. Kollmannsberger, SG. Nair, BM. Shuch, J. Huang, B. Simsek, J....

. 2025 ; 43 (2) : 189-200. [pub] 20240920

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010291

Grantová podpora
P30 CA008748 NCI NIH HHS - United States

PURPOSE: CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS: Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS: Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION: Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010291
003      
CZ-PrNML
005      
20250429134657.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.24.00773 $2 doi
035    __
$a (PubMed)39303200
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Motzer, Robert J $u Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY $1 https://orcid.org/0000000169252327
245    10
$a Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial / $c RJ. Motzer, A. Bex, P. Russo, Y. Tomita, HJ. Cutuli, C. Rojas, M. Gross-Goupil, G. Schinzari, B. Melichar, P. Barthélémy, A. Ruiz Garcia, J. Sosman, MO. Grimm, JC. Goh, C. Suarez, CK. Kollmannsberger, SG. Nair, BM. Shuch, J. Huang, B. Simsek, J. Spiridigliozzi, CW. Lee, M. van Kooten Losio, V. Grünwald
520    9_
$a PURPOSE: CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS: Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS: Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION: Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    12
$a karcinom z renálních buněk $x farmakoterapie $x chirurgie $7 D002292
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a ipilimumab $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D000074324
650    12
$a nádory ledvin $x farmakoterapie $x patologie $x chirurgie $7 D007680
650    12
$a lokální recidiva nádoru $7 D009364
650    12
$a nefrektomie $7 D009392
650    12
$a nivolumab $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D000077594
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Bex, Axel $u Netherlands Cancer Institute, Amsterdam, the Netherlands $u University College London, London, United Kingdom $1 https://orcid.org/0000000284992662
700    1_
$a Russo, Paul $u Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Tomita, Yoshihiko $u Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
700    1_
$a Cutuli, Hernan Javier $u Hospital Sirio Libanés, Buenos Aires, Argentina
700    1_
$a Rojas, Carlos $u Bradford Hill, Santiago, Chile
700    1_
$a Gross-Goupil, Marine $u Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France $1 https://orcid.org/0000000231764076
700    1_
$a Schinzari, Giovanni $u Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
700    1_
$a Melichar, Bohuslav $u Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Barthélémy, Philippe $u Institut de Cancérologie Strasbourg Europe, Strasbourg, France
700    1_
$a Ruiz Garcia, Abraham $u Hospital 1ro de Octubre, Mexico City, Mexico $1 https://orcid.org/0009000165733841
700    1_
$a Sosman, Jeffrey $u Northwestern University Medical Center, Chicago, IL
700    1_
$a Grimm, Marc-Oliver $u Jena University Hospital, Jena, Germany $1 https://orcid.org/0000000330848654
700    1_
$a Goh, Jeffrey C $u ICON Research, South Brisbane, QLD, Australia $1 https://orcid.org/000000033103146X
700    1_
$a Suarez, Cristina $u Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
700    1_
$a Kollmannsberger, Christian K $u BC Cancer, Vancouver, BC, Canada $1 https://orcid.org/000000026329761X
700    1_
$a Nair, Suresh G $u Lehigh Valley Health Network, Allentown, PA $1 https://orcid.org/0000000177639732
700    1_
$a Shuch, Brian M $u University of California Los Angeles, Los Angeles, CA $1 https://orcid.org/0000000320653570
700    1_
$a Huang, Jian $u Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
700    1_
$a Simsek, Burcin $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Spiridigliozzi, Julia $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Lee, Chung-Wei $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a van Kooten Losio, Maximiliano $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Grünwald, Viktor $u University Hospital Essen, Essen, Germany $1 https://orcid.org/0000000320837687
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 43, č. 2 (2025), s. 189-200
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39303200 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134652 $b ABA008
999    __
$a ok $b bmc $g 2311570 $s 1247372
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 43 $c 2 $d 189-200 $e 20240920 $i 1527-7755 $m Journal of clinical oncology $n J Clin Oncol $x MED00002596
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace